Cost-Effectiveness of Canagliflozin versus Sitagliptin as Add-on to Metforminin Patients with Type2 Diabetes Mellitus in Mexico
The validated IHE model (Economic and Health Outcomes [ECHO]-T2DM) was used to estimate the cost-effectiveness of canagliflozin versus sitagliptin for the treatment of type 2 diabetes mellitus (T2DM) as an add-on to metformin in Mexico. Data from a head-to-head, phase III clinical trial were used to simulate outcomes and resource use over 20 years. The results showed that canagliflozin (both 100 and 300 mg) was likely to be cost-effective versus sitagliptin in patients with T2DM who have inadequate glucose control on metformin, from the perspective of the Mexican health care system.
Value in Health Regional Issues 2015; 8: 8-19